Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded with efficacious biologics, including blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors Amgen’s Enbrel, AbbVie’s Humira, and Janssen’s Remicade, as well as non-TNF-α inhibitors such as Bristol-Myers Squibb’s Orencia and Roche/Genentech’s Rituxan and Actemra. In addition, Pfizer’s Jak inhibitor Xeljanz, the first targeted oral molecule approved for RA, has been approved for more than five years in the United States and is experiencing steady uptake. The RA therapy market is expected to become increasingly competitive with the upcoming approvals of additional agents and the entry of biosimilars, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.
- What is the patient share in RA of TNF-α inhibitors and other key drug classes?
- What are the demographic characteristics and clinical profiles of RA patients on biologics and Xeljanz?
- What are the key risk factors, comorbidities, and coprescribed/additional therapies by patient segment for RA?
- How do RA patient cohorts compare in care utilization and outcomes (physician visits and other healthcare encounters)?
- What are the reimbursed and out-of-pocket costs?
- What kind of insurance do RA patients have?
Patient Profiler provides disease-specific, patient-level analysis of key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.
- Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Patient Profiler (US)
- Patient Profiler Rheumatoid Arthritis 2018
- Please Note:
Author(s): Matthew W. Scutcher, MEng PhD; Maria Genco, Ph.D
Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.
In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry
He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.
Maria Genco, Ph.D., is an analyst on the Immune and Inflammatory Disorders group at Decision Resources Group, primarily focusing on rheumatoid arthritis and axial spondyloarthritis. She has authored market research reports on the RA disease landscape and commercial outlook of drugs, unmet needs in RA, and market access and reimbursement for RA targeted therapies. Prior to joining Decision Resources, Dr. Genco received her M.S. and Ph.D. in neuroscience from Brandeis University and a B.A. in neuroscience from Wellesley College.